石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01093 石药集团

未开盘 12-18 16:08:14

8.010

+0.490

+6.52%

最高8.040	最低7.430	成交量1.95亿
今开7.430	昨收7.520	日振幅8.11%
总市值922.91亿	流通市值922.91亿	总股本115.22亿
成交额15.44亿	换手率1.70%	流通股本115.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":8.01,"timestamp":1766045294004,"preClose":7.52,"halted":0,"volume":195489598,"delay":0,"floatShares":11522000000,"shares":11522000000,"eps":0.4079433801876663,"marketStatus":"未开盘","change":0.49,"latestTime":"12-18 16:08:14","open":7.43,"high":8.04,"low":7.43,"amount":1544018864,"amplitude":0.081117,"askPrice":8.01,"askSize":140000,"bidPrice":8,"bidSize":2560000,"shortable":3,"etf":0,"ttmEps":0.3919306969406968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766107800000},"marketStatusCode":0,"adr":0,"listingDate":772128000000,"exchange":"SEHK","adjPreClose":7.52,"dividendRate":0.031453,"openAndCloseTimeList":[[1766021400000,1766030400000],[1766034000000,1766044800000]],"volumeRatio":2.07659,"optionData":{"bulkOrders":[{"symbol":"CSP.HK","call":true,"expireDate":1772035200000,"strike":"7.75","timestamp":1766037012343,"price":0.74,"volume":314,"amount":464720,"type":"*"},{"symbol":"CSP.HK","call":true,"expireDate":1790611200000,"strike":"12.50","timestamp":1766034352083,"price":0.36,"volume":250,"amount":180000,"type":"*"}]},"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK","impliedVol":0.4137,"impliedVolPercentile":0.2805},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"1132338657","title":"石药集团 - Secukinumab注射剂的第三期临床试验获得初步结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132338657","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1132338657?lang=zh_cn&edition=full","pubTime":"2025-12-18 18:17","pubTimestamp":1766053020,"startTime":"0","endTime":"0","summary":"石药集团 - Secukinumab注射剂的第三期临床试验获得初步结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU0501845795.SGD","IE00B5MMRT66.SGD","LU1226288253.USD","LU0314109678.HKD","LU0072913022.USD","LU2039709279.SGD","IE0008369823.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU1807302812.USD","LU1328277881.USD","LU1152091754.HKD","LU0067412154.USD","LU1226287792.SGD","IE00B543WZ88.USD","IE00BZ08YR35.GBP","LU1993786604.SGD","LU0880133367.SGD","01093","SG9999004220.SGD","LU1152091168.USD","LU1226288170.HKD","BK1515","LU1226287875.USD","LU1226287529.USD","LU1813983027.USD","IE0008368742.USD","LU1960683339.HKD","BK1191","LU0140636845.USD","LU1008478684.HKD","HK0000165453.HKD","IE00BZ08YT58.USD","LU0315179316.USD","BK1521","IE00B031HY20.USD"],"gpt_icon":0},{"id":"2592971147","title":"石药创新再谋港股二次上市 首发募集资金使用率不足一半","url":"https://stock-news.laohu8.com/highlight/detail?id=2592971147","media":"经济参考网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592971147?lang=zh_cn&edition=full","pubTime":"2025-12-18 17:28","pubTimestamp":1766050106,"startTime":"0","endTime":"0","summary":"自2019年从石药集团（01093.HK）单独分拆至A股创业板上市后，石药创新制药股份有限公司（简称“石药创新”）日前再度向港交所递交上市申请，冲击“A+H”双重上市。回顾石药创新的发展历程，自2023年起公司多次收购石药集团旗下创新药资产，借此快速切入创新药赛道。战略转型的背后，逐渐频繁的资本运作也让公司与股东之间的内控治理成为市场关注的焦点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595542659.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1226287792.SGD","IE00BZ08YT58.USD","LU1226287529.USD","LU1807302812.USD","SG9999004220.SGD","IE0008368742.USD","IE0008369823.USD","LU0501845795.SGD","LU1993786604.SGD","IE00BZ08YR35.GBP","IE00B5MMRT66.SGD","HK0000165453.HKD","LU0315179316.USD","BK1521","LU1008478684.HKD","LU0314109678.HKD","IE00BZ08YS42.EUR","LU1960683339.HKD","LU0072913022.USD","LU0326950275.SGD","LU0067412154.USD","IE00B031HY20.USD","LU1328277881.USD","LU1813983027.USD","LU1152091168.USD","LU0880133367.SGD","BK1515","LU0140636845.USD","LU1226288170.HKD","LU1951186391.HKD","LU1226287875.USD","LU1226288253.USD","LU2039709279.SGD","LU1152091754.HKD","01093","IE00B543WZ88.USD","BK1191"],"gpt_icon":0},{"id":"2592513924","title":"创新药概念逆市上扬 石药集团(01093)午后升幅扩至近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592513924","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592513924?lang=zh_cn&edition=full","pubTime":"2025-12-18 13:21","pubTimestamp":1766035316,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念逆市上扬，石药集团 升5.98%，药明生物升1.97%，药明合联升1.56%，先声药业升1.51%，药明康德升1.28%。开源证券指出，当前纳入医保+商保的创新药大多处于未放量以及低基数阶段，随着医保支持创新药的政策红利持续释放，我们认为纳入双目录的创新药收入有望快速提升，患者有望持续受益，同时相关创新药企也随之迎来弹性增长。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/ZDQyZmM0MDNhYTRlOWFhOWE0NDBjZGFmOTc4ZmU3NDQzMjc2MzA4MTk4NA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971799","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","02269","159992","LU1688375341.USD","LU1794554557.SGD","LU0052750758.USD","BK1574","LU0181495838.USD","SG9999002463.SGD","LU0140636845.USD","02268","06978","BK1515","LU0856984785.SGD","LU1242518857.USD","LU3063872942.SGD","LU1807302812.USD","BK1589","LU1152091754.HKD","LU1226287792.SGD","IE00B031HY20.USD","BK1583","LU0307460666.USD","IE0008369823.USD","LU1328277881.USD","LU1226287875.USD","LU1242518931.SGD","LU1813983027.USD","IE00BZ08YS42.EUR","LU0348825331.USD","LU1008478684.HKD","IE00B5MMRT66.SGD","BK1191","LU0315179316.USD","LU0588546209.SGD","02096","SG9999002562.SGD","LU0320764599.SGD","02359","IE00BZ08YT58.USD","IE00B543WZ88.USD","LU1046422090.SGD","LU0039217434.USD","IE00BZ08YR35.GBP","LU0348735423.USD","LU0572944931.SGD","01093","LU0051755006.USD","LU0456827905.SGD","LU0501845795.SGD"],"gpt_icon":0},{"id":"2592910426","title":"12月17日港股药品及生物科技行业沽空数据盘点，信达生物、石药集团、三生制药沽空金额位居行业前三","url":"https://stock-news.laohu8.com/highlight/detail?id=2592910426","media":"证券之星APP","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592910426?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:06","pubTimestamp":1765965972,"startTime":"0","endTime":"0","summary":"证券之星消息，12月17日港交所披露数据显示，当日港股药品及生物科技行业的159只个股中有83只被沽空，总沽空股数为1.01亿股，总沽空金额为15.15亿元（港元），而当日药品及生物科技行业的总成交金额为89.09亿元（港元），沽空比例为17.0%。从沽空金额来看，信达生物、石药集团、三生制药沽空金额位居行业前三，分别为1.65亿港元、1.52亿港元、1.2亿港元。沽空与卖空含义相同，即在并不持有股票的前提下，通过借入股票获得筹码进而卖出。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217181708a45681d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251217181708a45681d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1521","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU0067412154.USD","LU2097828805.USD","IE0008368742.USD","LU2242644610.SGD","BK1515","BK1589","BK1583","LU1152091168.USD","LU1969619763.USD","LU2097828474.EUR","LU1328277881.USD","01801","LU1951186391.HKD","LU1152091754.HKD","SG9999004220.SGD","IE0008369823.USD","BK1593","LU1008478684.HKD","LU0072913022.USD","01093","LU0140636845.USD","LU1226287792.SGD","IE00BZ08YR35.GBP","LU1226288170.HKD","LU1813983027.USD","01530","LU1960683339.HKD","LU0315179316.USD","LU1807302812.USD","LU2097828714.EUR","LU1993786604.SGD","LU0455707207.USD","IE00B543WZ88.USD","LU2328871848.SGD","LU0326950275.SGD","LU2097828631.EUR","IE00BZ08YS42.EUR","HK0000165453.HKD","LU1226288253.USD","BK1191","BK1161","LU0502904849.HKD","LU1226287529.USD","LU2039709279.SGD","LU0501845795.SGD","LU0314109678.HKD","IE00BZ08YT58.USD"],"gpt_icon":0},{"id":"2592679039","title":"港股异动 | 石药集团(01093)尾盘涨近3% 贝派度酸片临床申请获受理 入局全新“非他汀类”降脂药","url":"https://stock-news.laohu8.com/highlight/detail?id=2592679039","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592679039?lang=zh_cn&edition=full","pubTime":"2025-12-17 15:32","pubTimestamp":1765956747,"startTime":"0","endTime":"0","summary":"消息面上，12月15日，据中国国家药品审评中心官网最新显示，石药集团旗下全资子公司石药集团欧意药业有限公司按化药注册分类3类申报的贝派度酸片临床申请获受理。值得一提的是，贝派度酸片原研药及仿制药均未尚未在国内上市。截至目前为止，国内已有甘李药业山东有限公司、江西施美药业、合肥立方制药、石药集团欧意药业4家药企申报的贝派度酸片临床申请均获受理，首仿之争已拉开帷幕。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0008368742.USD","LU1807302812.USD","LU2039709279.SGD","LU1226287792.SGD","BK1515","LU0067412154.USD","LU1008478684.HKD","IE00BZ08YS42.EUR","LU1152091754.HKD","LU1226288170.HKD","IE00B031HY20.USD","LU0880133367.SGD","LU1993786604.SGD","SG9999004220.SGD","LU0314109678.HKD","LU1226287875.USD","LU1328277881.USD","IE0008369823.USD","IE00B543WZ88.USD","LU1226288253.USD","LU0140636845.USD","LU0072913022.USD","01093","IE00BZ08YR35.GBP","HK0000165453.HKD","BK1521","LU1813983027.USD","LU1152091168.USD","LU0501845795.SGD","BK1191","LU1226287529.USD","IE00BZ08YT58.USD","LU1960683339.HKD","LU0315179316.USD","LU1951186391.HKD","IE00B5MMRT66.SGD","LU0326950275.SGD"],"gpt_icon":0},{"id":"2591632904","title":"英伟达连续布局13家企业，AI制药3个方向梳理（附列表）","url":"https://stock-news.laohu8.com/highlight/detail?id=2591632904","media":"投研大叔","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591632904?lang=zh_cn&edition=full","pubTime":"2025-12-13 19:40","pubTimestamp":1765626014,"startTime":"0","endTime":"0","summary":"今天介绍下AI制药，英伟达在过去2年投资13家AI药企，推出BioNeMo生物分子AI框架已经覆盖上百家药企，英硅智能ISM001-055进入临床III期，成为首个跨越临床II期的AI药物，从之前的布局到如今逐渐突破，商业价值正在逐渐被验证。从大叔个人来看，还有一些罕见病，由于患者少，研发不划算，而AI能快速低成本设计药物，让更多罕见病有药可治。近期热门文章HW组建医疗卫生军团，AI医疗爆发！","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213194757a4470c58&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1280957306.USD","01093","NVD","SGXZ81514606.USD","LU1988902786.USD","IE00BJJMRY28.SGD","LU2191332357.HKD","NVDD","NVDA","02228","LU2089284900.SGD","LU2592432038.USD","LU0719512351.SGD","LU0444973449.USD","IE00BDCRKT87.USD","LU2249611893.SGD","LU0157215616.USD","LU1145028129.USD","LU2420271590.USD","NVIW.SI","LU2065171311.SGD","NVD2.UK","NVDS.UK","03759","LU0096362180.USD","02196","IE000YTNTUN2.SGD","06127","IE000ITXATA3.USD","LU1496350171.SGD","LU2237438978.USD","2NVD.UK","02359","SNVD.UK","LU2602419157.SGD","LU0274383776.USD","NVD3.UK","NVDS","LU1839511570.USD","LU2505996681.GBP","LU2473716301.USD","LU2463028550.USD","LU1642822529.SGD","3NVD.UK","LU1914381329.SGD","LU0158827948.USD","SG9999004303.SGD","LU2505996509.AUD","IE0034235188.USD","NVDY","06821","NVDX","LU2860962120.EUR","LU0308772762.SGD","LU0320765059.SGD","NVDU"],"gpt_icon":1},{"id":"2591635299","title":"瞩目，石药集团又一重磅药物新适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2591635299","media":"北京药研汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591635299?lang=zh_cn&edition=full","pubTime":"2025-12-13 08:03","pubTimestamp":1765584214,"startTime":"0","endTime":"0","summary":"2025年12月12日，石药集团宣布，本集团全资子公司石药集团欧意药业有限公司开发的盐酸伊立替康脂质体注射液的新适应症获批上市。目前，石药集团的盐酸伊立替康脂质体注射液用于胰腺癌术后辅助治疗的关键注册III期临床试验正在进行中。随着石药集团该产品的第2项适应症获批上市，以及后续适应症临床试验的顺利推进，必将为广大胰腺癌患者提供新的治疗希望。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213081638a445d064&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251213081638a445d064&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1226288170.HKD","IE0008368742.USD","LU0880133367.SGD","LU0072913022.USD","IE00BZ08YR35.GBP","LU1226288253.USD","LU0501845795.SGD","LU1152091754.HKD","HK0000165453.HKD","LU0315179316.USD","IE0008369823.USD","LU1226287792.SGD","LU1226287529.USD","LU1813983027.USD","IE00B031HY20.USD","LU1328277881.USD","LU1226287875.USD","IE00BZ08YT58.USD","LU1807302812.USD","LU2039709279.SGD","LU0314109678.HKD","LU0326950275.SGD","IE00B543WZ88.USD","BK1191","LU0140636845.USD","LU1008478684.HKD","BK1521","LU1152091168.USD","IE00BZ08YS42.EUR","LU1960683339.HKD","IE00B5MMRT66.SGD","BK1515","LU0067412154.USD","LU1951186391.HKD","LU1993786604.SGD","SG9999004220.SGD","01093"],"gpt_icon":0},{"id":"2590703195","title":"石药集团(01093)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590703195","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590703195?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:24","pubTimestamp":1765535073,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的盐酸伊立替康脂质体注射液的新适应症已获得中华人民共和国国家药品监督管理局上市批准。本次获批的适应症为该产品在中国获批的第二个适应症，亦是伊立替康脂质体注射液在国内首次获批用于胰腺癌一线治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：多恩益®(盐酸伊立替康脂质体注射液)的新适应症获上市批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B543WZ88.USD","LU1226287792.SGD","LU2039709279.SGD","LU1226288253.USD","BK1191","IE0008369823.USD","LU0315179316.USD","IE0008368742.USD","LU0072913022.USD","LU0880133367.SGD","IE00BZ08YR35.GBP","LU1152091168.USD","IE00B5MMRT66.SGD","LU1993786604.SGD","LU1152091754.HKD","LU1328277881.USD","LU0140636845.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU1226287529.USD","BK1521","LU1807302812.USD","HK0000165453.HKD","SG9999004220.SGD","LU0067412154.USD","LU1960683339.HKD","LU0326950275.SGD","LU0314109678.HKD","LU1226288170.HKD","BK1515","IE00BZ08YS42.EUR","LU0501845795.SGD","IE00B031HY20.USD","LU1008478684.HKD","LU1951186391.HKD","01093","LU1813983027.USD"],"gpt_icon":0},{"id":"2591963526","title":"每日卖空追踪 | 石药集团 12月12日卖空量成交861.6万股，卖空比例为8.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591963526","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591963526?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:30","pubTimestamp":1765528217,"startTime":"0","endTime":"0","summary":"石药集团北京时间12月12日，跌0.39%，卖空量成交861.6万股，较上一交易日减少64.93%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216490195398ae6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121216490195398ae6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BZ08YT58.USD","IE0008369823.USD","LU1993786604.SGD","LU0880133367.SGD","LU0326950275.SGD","LU1226287875.USD","LU1328277881.USD","LU0315179316.USD","IE00BZ08YS42.EUR","LU1008478684.HKD","LU1813983027.USD","LU0072913022.USD","LU1152091754.HKD","LU0067412154.USD","LU2039709279.SGD","LU0314109678.HKD","IE00BZ08YR35.GBP","LU0501845795.SGD","IE00B5MMRT66.SGD","LU1226288170.HKD","LU1226288253.USD","LU1152091168.USD","HK0000165453.HKD","LU1951186391.HKD","BK1521","LU1226287792.SGD","IE00B031HY20.USD","IE0008368742.USD","LU1960683339.HKD","BK1191","BK1515","SG9999004220.SGD","IE00B543WZ88.USD","LU1226287529.USD","LU1807302812.USD","LU0140636845.USD","01093"],"gpt_icon":0},{"id":"2590233595","title":"【券商聚焦】交银国际：创新药增量支付空间持续扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2590233595","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590233595?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:02","pubTimestamp":1765501348,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，10月以来，内资通过港股通持有医药股的比例小幅下降，外资持仓整体平稳，内外资加大创新药布局的大方向不变。该机构指，本周医保+商保双目录落地，医保谈判新增品种成功率创近年新高，续约品种降价幅度相对温和。该机构认为商保资金的引入将为创新药支付带来重要增量资金，进一步优化多元支付体系。该机构看好医保新纳入品种/适应症在2026年的销售放量，以及首版商保目录的实际执行和支付情况。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971425","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU1951186391.HKD","LU2778985437.USD","LU0359202008.SGD","BK1161","01093","LU1242518931.SGD","LU0880133367.SGD","LU2328871848.SGD","LU0181495838.USD","03329","HK0000165453.HKD","01877","LU2097828631.EUR","LU0516423091.SGD","LU2097828557.USD","09926","LU2242644610.SGD","LU0348766576.USD","LU0359201612.USD","LU0043850808.USD","02142","LU2097828714.EUR","LU0540923850.HKD","LU1969619763.USD","LU0456827905.SGD","01801","09995","SG9999002463.SGD","06978","LU1226287529.USD","LU1961090484.USD","LU2039709279.SGD","02616","LU0708995583.HKD","06160","LU1993786604.SGD","IE00B0JY6N72.USD","LU1794554557.SGD","159992","LU0067412154.USD","01177","06185","09688","LU0417516738.SGD","02269","SG9999004220.SGD","LU1770034418.SGD","LU0502904849.HKD","BK1588"],"gpt_icon":0},{"id":"2590800685","title":"新股消息 | 石药创新(300765.SZ)递表港交所 为全球最大化学合成咖啡因生产商","url":"https://stock-news.laohu8.com/highlight/detail?id=2590800685","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590800685?lang=zh_cn&edition=full","pubTime":"2025-12-10 21:34","pubTimestamp":1765373692,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所12月10日披露，石药创新制药股份有限公司向港交所主板递交上市申请，中信证券为其独家保荐人。全球最大的咖啡因生产商。根据弗若斯特沙利文的资料，自2020年至2024年，按收入和出货量计，该公司始终保持着全球最大化学合成咖啡因生产商地位。财务资料收入2022年度、2023年度、2024年度及2025年截至7月31日止七个月，该公司收入分别约为28.38亿元、25.39亿元、19.81亿元、12.41亿元人民币。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380106.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0314109678.HKD","LU0140636845.USD","HK0000165453.HKD","LU1960683339.HKD","HEXmain","BK1515","BK0226","LU1226288253.USD","LU1813983027.USD","IE00BZ08YR35.GBP","LU1328277881.USD","LU0501845795.SGD","300765","LU1226287792.SGD","LU1226288170.HKD","LU1993786604.SGD","LU1807302812.USD","IE00B543WZ88.USD","IE00BZ08YT58.USD","IE00BZ08YS42.EUR","LU1951186391.HKD","LU0880133367.SGD","IE0008368742.USD","LU1152091754.HKD","IE0008369823.USD","SG9999004220.SGD","LU1226287529.USD","LU0326950275.SGD","LU2039709279.SGD","LU0315179316.USD","LU1008478684.HKD","LU1226287875.USD","IE00B031HY20.USD","BK1521","01093","IE00B5MMRT66.SGD","LU1152091168.USD","LU0072913022.USD","LU0067412154.USD","BK1191"],"gpt_icon":0},{"id":"2590258591","title":"石药集团(01093)：重组全人源抗ACTRIIA / IIB单克隆抗体(JMT206) 在美国获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590258591","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590258591?lang=zh_cn&edition=full","pubTime":"2025-12-10 18:20","pubTimestamp":1765362040,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，集团开发的重组全人源抗ActRIIA/IIB单克隆抗体(该产品)已获美国食品药品监督管理局批准，可在美国开展临床试验。同时，该产品亦可协助GLP-1受体激动剂实现更高质量的减重效果。本次获批的临床适应症为肥胖或超重合并至少一种体重相关合并症人群的体重管理。临床前研究显示，该产品表现出较高的生物利用度以及良好的有效性和安全性，具有较高的临床开发价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药集团(01093)：重组全人源抗ACTRIIA / IIB单克隆抗体(JMT206) 在美国获临床试验批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1226288170.HKD","IE0008369823.USD","LU1960683339.HKD","LU0315179316.USD","IE00BZ08YR35.GBP","LU1226288253.USD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1226287875.USD","HK0000165453.HKD","LU0326950275.SGD","LU1807302812.USD","LU0140636845.USD","LU1226287792.SGD","LU1328277881.USD","LU1993786604.SGD","BK1515","SG9999004220.SGD","LU1152091754.HKD","IE00BZ08YT58.USD","LU0501845795.SGD","IE00B543WZ88.USD","LU1008478684.HKD","LU0314109678.HKD","LU0067412154.USD","LU2039709279.SGD","LU1813983027.USD","LU0880133367.SGD","LU1951186391.HKD","IE00B031HY20.USD","LU1152091168.USD","BK1191","BK1521","IE00B5MMRT66.SGD","LU1226287529.USD","IE0008368742.USD","01093"],"gpt_icon":0},{"id":"2590610584","title":"每日卖空追踪 | 石药集团 12月10日卖空量成交858.2万股，卖空比例为8.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590610584","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590610584?lang=zh_cn&edition=full","pubTime":"2025-12-10 16:30","pubTimestamp":1765355418,"startTime":"0","endTime":"0","summary":"石药集团北京时间12月10日，涨3.19%，卖空量成交858.2万股，较上一交易日减少69.68%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016323495353c3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025121016323495353c3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0008369823.USD","IE00BZ08YR35.GBP","LU1813983027.USD","IE00BZ08YT58.USD","LU1951186391.HKD","BK1515","IE00B031HY20.USD","LU1226288170.HKD","LU1226287529.USD","LU0326950275.SGD","LU0314109678.HKD","LU1960683339.HKD","BK1191","HK0000165453.HKD","SG9999004220.SGD","LU1226288253.USD","LU2039709279.SGD","LU1993786604.SGD","IE00BZ08YS42.EUR","IE00B5MMRT66.SGD","01093","LU0140636845.USD","LU0880133367.SGD","LU1226287792.SGD","LU0072913022.USD","IE00B543WZ88.USD","LU1008478684.HKD","LU0315179316.USD","BK1521","LU0501845795.SGD","LU1152091754.HKD","LU1152091168.USD","LU1807302812.USD","LU1226287875.USD","LU1328277881.USD","LU0067412154.USD","IE0008368742.USD"],"gpt_icon":0},{"id":"2590309346","title":"港股异动 | 石药集团(01093)尾盘涨超3% 司美格鲁肽注射液第二项上市许可申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2590309346","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590309346?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:17","pubTimestamp":1765351061,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，石药集团尾盘涨超3%，截至发稿，涨2.92%，报7.75港元，成交额5.15亿港元。消息面上，12月8日，石药集团发布公告，公司附属公司石药集团百克(山东)生物制药股份有限公司开发的司美格鲁肽注射液的第二项上市许可申请已获中华人民共和国国家药品监督管理局受理。此前，该产品拟用于成人2型糖尿病血糖控制的适应症上市许可申请已于2025年8月获国家药监局受理。公告称，本次申请基于一项Ⅲ期临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 石药集团(01093)尾盘涨超3% 司美格鲁肽注射液第二项上市许可申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0314109678.HKD","IE0008368742.USD","IE00B031HY20.USD","SG9999004220.SGD","LU1813983027.USD","IE00B5MMRT66.SGD","LU0326950275.SGD","LU0501845795.SGD","LU0140636845.USD","IE0008369823.USD","LU1008478684.HKD","LU1807302812.USD","IE00BZ08YR35.GBP","LU2039709279.SGD","LU0315179316.USD","HK0000165453.HKD","LU1152091168.USD","BK1191","BK1521","LU1226288170.HKD","LU1152091754.HKD","LU1226287792.SGD","LU0880133367.SGD","LU0072913022.USD","LU0067412154.USD","LU1960683339.HKD","BK1515","LU1328277881.USD","LU1226288253.USD","LU1993786604.SGD","LU1951186391.HKD","IE00BZ08YT58.USD","IE00B543WZ88.USD","LU1226287529.USD","IE00BZ08YS42.EUR","01093","LU1226287875.USD"],"gpt_icon":0},{"id":"2590372001","title":"国元国际：给予石药集团(01093)“买入”评级 创新药研发快速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2590372001","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590372001?lang=zh_cn&edition=full","pubTime":"2025-12-10 11:40","pubTimestamp":1765338018,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国元国际发布研报称，给予石药集团“买入”评级，目标价10.11港元，公司积极布局创新药，研发投入加大，出海成果突出，公司持续高强度投入研发，已构建国际化管线与领先平台，出海成果显著。SYS6010获FDA三项快速通道资格，获得NMPA突破性疗法认定，单药用于EGFR-TKI和含铂化疗治疗失败的EGFR突变阳性的NSCLC，目前进行三期临床，有望26年递交申请上市，有望实现大金额BD。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","01093","159992"],"gpt_icon":0},{"id":"2590375556","title":"每日卖空追踪 | 石药集团 12月09日卖空量成交1185.8万股，卖空比例为11.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590375556","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590375556?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:30","pubTimestamp":1765269017,"startTime":"0","endTime":"0","summary":"石药集团北京时间12月09日，涨0.53%，卖空量成交1185.8万股，较上一交易日减少29.27%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163217a72cf0e1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209163217a72cf0e1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00B5MMRT66.SGD","LU0072913022.USD","LU0315179316.USD","LU1152091168.USD","LU0140636845.USD","LU1226288253.USD","LU1152091754.HKD","LU1960683339.HKD","LU1328277881.USD","LU0314109678.HKD","BK1521","LU2039709279.SGD","LU1226288170.HKD","LU1226287875.USD","IE00B543WZ88.USD","BK1515","LU0501845795.SGD","IE00BZ08YR35.GBP","LU0326950275.SGD","IE00BZ08YS42.EUR","BK1191","LU1226287792.SGD","IE0008369823.USD","LU1813983027.USD","LU1993786604.SGD","LU0880133367.SGD","LU1951186391.HKD","01093","LU1008478684.HKD","IE00B031HY20.USD","HK0000165453.HKD","IE0008368742.USD","SG9999004220.SGD","IE00BZ08YT58.USD","LU0067412154.USD","LU1226287529.USD","LU1807302812.USD"],"gpt_icon":0},{"id":"2590367035","title":"【券商聚焦】交银国际：2025年医保+商保双目录落地 多元支付体系盘活创新药增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367035","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590367035?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:59","pubTimestamp":1765241994,"startTime":"0","endTime":"0","summary":"调整后的目录中，药品总数增至3,253种。新版目录将于2026年1月1日正式实施。该机构认为，更多新药进入目录有助于提升临床用药水平，及创新药行业整体研发回报率；商保资金的引入将为创新药支付带来重要增量资金，为多元化支付体系的建立奠定基础。百济有两款产品纳入商保创新药目录，信达、和黄各有一款纳入。同时重点关注首批商保目录的实际执行和支付情况、名单及定价的动态调整以及真实世界数据积累带来的长期发展机会。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1971149","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01801","LU0880133367.SGD","BK1576","02616","159992","LU1226288170.HKD","06185","LU0140636845.USD","IE00B0JY6N72.USD","LU0348766576.USD","LU1813983027.USD","09688","01177","03329","LU1951186391.HKD","LU0327786744.USD","IE00BZ08YR35.GBP","09995","LU1719994722.HKD","LU0181495838.USD","BK1610","LU0516423091.SGD","LU0417516902.SGD","06160","06978","BK1141","BK1191","LU0348784397.USD","LU1969619763.USD","LU2399975544.HKD","BK1147","IE00B543WZ88.USD","BK1588","01877","BK1574","LU0348783233.USD","09926","02142","LU0456827905.SGD","02269","LU0572944931.SGD","LU1720050803.USD","01093","LU2476274308.USD","LU0326950275.SGD","LU2039709279.SGD","BK1161","LU0348767384.USD","LU0708995583.HKD","LU1770034418.SGD"],"gpt_icon":0},{"id":"2590367683","title":"石药创新制药拟将阿卡波糖项目节余募资3621.73万元永久补流","url":"https://stock-news.laohu8.com/highlight/detail?id=2590367683","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590367683?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:33","pubTimestamp":1765240382,"startTime":"0","endTime":"0","summary":"中访网数据 石药创新制药股份有限公司于2025年12月5日召开董事会，审议通过了关于部分募集资金投资项目结项并将节余募集资金永久补充流动资金的议案。公司拟将已实施完毕的“阿卡波糖绿色工厂升级技术改造项目”结项，并将该项目节余的募集资金及利息合计3,621.73万元永久补充流动资金，用于与主营业务相关的经营活动。资金划转后，公司将注销相关募集资金专户，相应的监管协议随之终止。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251209/31852177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1191","LU0067412154.USD","BK1574","IE00B5MMRT66.SGD","LU0880133367.SGD","LU0501845795.SGD","LU1226288253.USD","01093","IE00BZ08YS42.EUR","LU1226287875.USD","IE00BZ08YT58.USD","LU1152091168.USD","01477","LU1807302812.USD","HK0000165453.HKD","IE0008369823.USD","BK1515","IE0008368742.USD","LU0326950275.SGD","LU1993786604.SGD","LU1226287529.USD","LU1152091754.HKD","LU1226287792.SGD","LU0314109678.HKD","LU1328277881.USD","LU0140636845.USD","LU1960683339.HKD","LU1226288170.HKD","IE00BZ08YR35.GBP","LU0315179316.USD","LU2039709279.SGD","LU0072913022.USD","SG9999004220.SGD","BK1521","LU1008478684.HKD","LU1813983027.USD","IE00B031HY20.USD","IE00B543WZ88.USD","LU1951186391.HKD"],"gpt_icon":0},{"id":"2590505350","title":"Cosmo脱发新药三期临床告捷；石药集团双靶点新药FDA临床批准；百奥赛图B7H3/PTK7双抗ADC获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590505350","media":"药财社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590505350?lang=zh_cn&edition=full","pubTime":"2025-12-08 19:02","pubTimestamp":1765191720,"startTime":"0","endTime":"0","summary":"2石药集团双靶点新药FDA临床批准12月5日，石药集团宣布，本集团开发的GLP-1/GIP受体双偏向性激动多肽注射液已获得美国食品药品监督管理局批准，可在美国开展临床试验。3百奥赛图B7H3/PTK7双抗ADC获FDA批准2025年12月5日，百奥赛图宣布，其合作伙伴IDEAYA 公司已获得美国FDA的临床试验用新药批准，推进同类首创B7H3/PTK7双特异性抗体偶联物项目的I期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208200527a72b1d02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208200527a72b1d02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01093","LU1807302812.USD","SG9999004220.SGD","IE0008369823.USD","LU1226288170.HKD","LU1328277881.USD","LU0140636845.USD","IE00B031HY20.USD","LU1226287792.SGD","LU1152091168.USD","LU0067412154.USD","IE00B5MMRT66.SGD","IE00B543WZ88.USD","02315","BK1521","IE00BZ08YS42.EUR","LU2039709279.SGD","LU0326950275.SGD","LU0880133367.SGD","LU1226287529.USD","IE00BZ08YT58.USD","LU1226287875.USD","LU0501845795.SGD","LU1226288253.USD","LU0314109678.HKD","LU1813983027.USD","BK1515","LU1008478684.HKD","LU0072913022.USD","IE00BZ08YR35.GBP","LU0315179316.USD","BK1161","LU1960683339.HKD","LU1152091754.HKD","LU1993786604.SGD","LU1951186391.HKD","BK1191","IE0008368742.USD","HK0000165453.HKD"],"gpt_icon":1},{"id":"2589382961","title":"36个品种拟进院，独家品种占比超35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2589382961","media":"赛柏蓝","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589382961?lang=zh_cn&edition=full","pubTime":"2025-12-06 19:21","pubTimestamp":1765020078,"startTime":"0","endTime":"0","summary":"36款拟引进的新药中，独家品种占比超35%，涉及复方鳖甲软肝片、地达西尼胶囊、递法明片等潜力品种；另有12个国采品种在列，石药集团、华海药业、倍特药业等集采中选企业优势十足。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206192444a7278966&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251206192444a7278966&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06887","02348","01093","BK1191"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cspc.com.hk","stockEarnings":[{"period":"1week","weight":-0.0322},{"period":"1month","weight":-0.0445},{"period":"3month","weight":-0.247},{"period":"6month","weight":0.002},{"period":"1year","weight":0.6704},{"period":"ytd","weight":0.6179}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":-0.0347},{"period":"3month","weight":-0.0405},{"period":"6month","weight":0.0824},{"period":"1year","weight":0.2928},{"period":"ytd","weight":0.2696}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石药集团有限公司是一家主要从事生产及销售药品的投资控股公司。该公司通过三个分部运营其业务。成药分部从事研发、生产及销售药品以及授权业务。原料产品分部从事生产及销售粉状维生素C及抗生素产品。功能食品及其他分部从事制造及销售功能食品产品（包括咖啡因食物添加剂、无水葡萄糖、阿卡波糖及维生素C含片）、提供医疗服务及其他。该公司的产品治疗领域包括神经系统、抗肿瘤、抗感染、心血管、呼吸系统、消化代谢等其他领域。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.516129,"avgChangeRate":0.005459},{"month":2,"riseRate":0.741935,"avgChangeRate":0.096733},{"month":3,"riseRate":0.483871,"avgChangeRate":0.020489},{"month":4,"riseRate":0.612903,"avgChangeRate":0.062074},{"month":5,"riseRate":0.612903,"avgChangeRate":0.047434},{"month":6,"riseRate":0.322581,"avgChangeRate":0.003636},{"month":7,"riseRate":0.375,"avgChangeRate":0.009082},{"month":8,"riseRate":0.4375,"avgChangeRate":0.010009},{"month":9,"riseRate":0.5,"avgChangeRate":0.000153},{"month":10,"riseRate":0.5625,"avgChangeRate":0.010484},{"month":11,"riseRate":0.46875,"avgChangeRate":0.00638},{"month":12,"riseRate":0.46875,"avgChangeRate":-0.016866}],"exchange":"SEHK","name":"石药集团","nameEN":"CSPC PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}